These efforts have almost exclusively investigated tumour characteristics, such as programmed death ligand 1 (PDL1) expression, mutational burden and mismatch-repair deficiency.6,7 Thus far, little is known about who is at risk for autoimmune toxicities or when they will occur, concerns that seem more likely related to host immune function than to tumour features. Here, CD274 is linked to neoplasm.